Cervomed reports third quarter 2024 financial results and provides corporate updates

- reported last patient, last visit in its rewind-lb phase 2b clinical trial evaluating neflamapimod in patients with early-stage dementia with lewy bodies (dlb) in october 2024; topline data expected in december 2024 –
CRVO Ratings Summary
CRVO Quant Ranking